



SeQuent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare

Mumbai, January 22, 2016: SeQuent Scientific Limited today announced that it is acquiring a controlling stake in Indo Phyto Chemicals Pvt Ltd (IPC), a New Delhi based pharmaceutical Company, focused on Female Healthcare. The transaction is subject to customary closing conditions.

IPC is a fully integrated company with a portfolio of steroids and hormonal APIs and having its manufacturing base in Uttarakhand. The company has capabilities in both fermentation and chemical synthesis, giving it a unique ability to produce APIs from the basic starting materials that are extracted from plants. IPC currently produces 14 APIs and has an aggressive R&D pipeline including 20 more under development. The company has already commenced filings in the regulated markets.

Under the terms of the agreement, SeQuent is acquiring 51% of IPC and the remaining 49% will continue to be held by the Promoters of IPC, who will also join the Sequent management team in driving the business.

Commenting on the development, **Mr. Manish Gupta, Managing Director of SeQuent Scientific** said that *"We are pleased to announce the acquisition of a majority stake in IPC, which gives us an entry into the niche female healthcare segment, with specific focus on steroids and hormones. This is in line with our business strategy of focusing on niche and complex segments in the market place. With IPC's enhanced product portfolio and our strong global foot print, we believe the business will enter the next orbit of growth."*

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-SEQUENT/512529) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), niche Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

SeQuent's Animal Health business is operated through its subsidiary Alivira Animal Health Ltd and SeQuent is poised to emerge as a global powerhouse in animal health business, built on a platform of superior quality and compliance.

For Queries, please contact

Kannan P R

Chief Financial Officer

Tel: +91 80 67840327

Kannan.pr@sequent.in

Ankit Gupta

Christensen Investor Relations

Tel: +91 22 42150210

ankitgupta@christensenir.com

SeQuent Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle',

Plot No. E7, Road No. 22,

Wagle Industrial Area, Thane (W), Maharashtra,

India

CIN: L99999MH1985PLC036685

BSE Code: 512529

ISIN: INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.